24P Patient-reported outcomes and long-term toxicity in clinical stage I testicular germ cell tumour survivors treated under a risk-adapted strategy

ESMO rare cancers. 2026 Open access

Read full text
Authors: P. Capdevila Gaudens, J. Aparicio
DOI: 10.1016/j.esmorc.2026.100231
Cited by: 0

Abstract

Clinical stage I (CSI) testicular germ cell tumours (TGCT) have near-universal cancer-specific survival. As oncologic outcomes converge, long-term comorbidities and health-related quality of life (HRQoL) should guide the choice between surveillance and adjuvant therapy.

Fields of Study & Subjects

Testicular diseases and treatments Childhood Cancer Survivors' Quality of Life Cancer survivorship and care

Publication details

Journal / source
ESMO rare cancers.
Volume
5
Pages
100231–100231
Publication date
1 March 2026
Language
EN